Abstract:Introduction: Short chain fatty acids (propionate, butyrate and acetate) are produced in the colon by the anaerobic fermentation of carbohydrates by the gut bacteria, and account for many physiological interactions between the gut microbiota and the host.Among these, it has very recently been shown that gut-derived propionate regulate blood pressure by inducing vasodilation.The liver is the main site of propionate clearance.We have recently shown that propionate levels are increased in patients with cirrhosis and correlates with the severity of portal hypertension, raising the possibility that propionate plays a pathogenic role in the hemodynamic abnormalities of cirrhosis, characterized by arterial hypotension, portal hypertension and arterial vasodilation.The aim of this study was to assess, in an animal model of cirrhosis, if propionate contributes to cirrhosis hemodynamic derangement.Methods: We studied a total of 42 rats with cirrhosis induced by common bile duct ligation and sham operated rats 28 days after the surgery.An additional group of CBDL rats was treated with metronidazole from day 24-28 after the surgery, since this is the most effective therapy to decrease gut propionate production.Main readouts were plasma and cecal propionate levels, and systemic and splanchnic hemodynamics (portal pressure (PP), mean arterial pressure (MAP) and superior mesenteric artery blood flow (SMBF).Results: As expected CBDL rats showed an increased portal pressure (PP), decreased mean arterial pressure (MAP) and increased superior mesenteric artery blood flow (SMABF).Further, these rats showed significantly increased plasma propionate levels as compared with sham rats (0.13 vs 0.7 mM respectively;p=0.047), together with a significant down-regulation in the liver expression of the enzymes responsible for propionate metabolism (PCC, MUT and MCEE).Cecal content did not show a significant increase in propionate in CBDL rats, altogether suggesting that increased propionate was the result of impaired liver metabolism.Metronidazole treatment induced a marked decrease in cecal propionate and decreased plasma propionate in CBDL rats.This was associated with a decrease in PP (from 14.7 mmHg in untreated rats to 12.9; p=0.038) and in SMABF (from 24.4 to 17.5 ml/min; p=0.024), and an increase in MAP (from 85 to 96 mmHg; p=0.001).In metronidazole treated rats, restoration of high plasma propionate levels with an i.v.infusion of propionate abrogated beneficial hemodynamic effects of metronidazole.Conclusion: Metronidazol treatment improves systemic and splanchnic hemodynamics in cirrhotic rats.This effect is, at least in part, mediated by a decrease in propionate, since it is reversed by restoring plasma propionate levels.Altogether our data suggest that decreasing circulating propionate might improve hemodynamics in cirrhosis.

Simvastatin Lowers Portal Pressure in Rats with Cirrhosis and Portal Hypertension Via Inhibiting Activation of P38 MAPK Signaling Pathway

The effects of statins in treatment of portal hypertension in cirrhotic patients and rats: a Meta-analysis

Therapeutic effects of arotinolol,propranolol and carvedilol on portal hypertension in cirrhotic rats

Atorvastatin lowers portal pressure in cirrhotic rats by inhibition of RhoA/Rho-kinase and activation of endothelial nitric oxide synthase

Inhibition of Janus kinase-2 signalling pathway ameliorates portal hypertensive syndrome in partial portal hypertensive and liver cirrhosis rats

[The Anti-Portal Hypertension Effect of Oleanolic Acid in CCl4-induced Cirrhosis Rats].

Combined Administration of Propranolol + AG490 Offers Better Effects on Portal Hypertensive Rats with Cirrhosis

Effect of Simvastatin on Regression of Pressure Overload-Induced Rat's Myocardial Fibrosis and Its Relationship with Monocyte Chemoattractant Protein-1

Celecoxib Ameliorates Portal Hypertension of the Cirrhotic Rats Through the Dual Inhibitory Effects on the Intrahepatic Fibrosis and Angiogenesis.

Sodium ferulate lowers portal pressure in rats with secondary biliary cirrhosis through the RhoA/Rho-kinase signaling pathway: a preliminary study

Expression of connective tissue growth factor and its down-regulation by simvastatin administration in pulmonary hypertensive rats

Cediranib Ameliorates Portal Hypertensive Syndrome Via Inhibition of VEGFR-2 Signaling in Cirrhotic Rats

Effects of Chaihu-Shugan-San and Shen-Ling-Bai-Zhu-San on P38 MAPK Pathway in Kupffer Cells of Nonalcoholic Steatohepatitis

Experimental study on activation of mTOR signaling pathway promoting mesenteric angiogenesis in portal hyper-tensive rats

Experimental study of activation of mtor/p70s6k signaling pathway in liver cirrhotic portal hypertension

Simvastatin protects against the development of monocrotaline-induced pulmonary hypertension in rats via a heme oxygenase-1–dependent pathway

Attenuation of Portal Hypertension by Natural Taurine in Rats with Liver Cirrhosis.

Simvastatin Ameliorates Total Liver Ischemia/reperfusion Injury Via KLF2-mediated Mechanism in Rats.

Depressive Effect of Natural Taurine on Portal Hypertension on Rats with Liver Cirrhosis

Changes of hemodynamics and portal vein pressure in the progression of portal hypertension in rats

Antioxidant Properties of Celecoxib Reduce Hepatic Vascular Resistance and Portal Pressure in Cirrhotic Rats